Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter

M. Vytrisalova, T. Touskova, K. Ladova, L. Fuksa, V. Palicka, P. Matoulkova, P. Horak, J. Stepan,

. 2015 ; 18 (4) : 608-16. [pub] 20150224

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010667

OBJECTIVES: Low adherence to treatment with bisphosphonates significantly impedes its effectiveness. The objectives were: (1) to compare adherence to oral weekly and monthly bisphosphonates with emphasis on dosing instructions; and (2) to study associations between adherence and beliefs about the bisphosphonate treatment among women ≥ 55 years. METHODS: A multicenter survey was performed in secondary-care patients with osteoporosis. Osteoporosis Specific Morisky Medication Adherence Scale (OS-MMAS), questions on compliance with five dosing instructions and Beliefs about Medicines Questionnaire (BMQ) Specific were used. RESULTS: As many as 363 questionnaires (response rate 95%) were analyzed. Respondents (mean age 69 years) were treated with weekly bisphosphonates (37%) or monthly ibandronate (63%). Based on OS-MMAS, 67% of respondents showed high adherence with no differences between the subgroups. Only 44% of respondents were compliant with all dosing instructions. Compliance with dosing instructions concerning time interval (fasting and staying upright) was 71% in weekly and 52% in monthly subgroups, respectively (p < 0.001). Compliance with dosing instructions correlated positively with education (p = 0.009). The mean BMQ necessity score of 18.4 was greater than the mean BMQ concerns score of 13.3. OS-MMAS score correlated with necessity (p = 0.010). Persistence derived from OS-MMAS correlated with both necessity (p = 0.014) and concerns (p = 0.041). CONCLUSION: Despite relatively high adherence to the treatment, most patients do not follow dosing instructions. Reduced bioavailability, particularly of monthly ibandronate, can be expected in clinical practice. Adherence-related outcomes are associated with beliefs about the oral treatment with bisphosphonates.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010667
003      
CZ-PrNML
005      
20180117094406.0
007      
ta
008      
160408s2015 enk f 000 0|eng||
009      
AR
024    7_
$a 10.3109/13697137.2014.995164 $2 doi
024    7_
$a 10.3109/13697137.2014.995164 $2 doi
035    __
$a (PubMed)25495333
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vytrisalova, M $u Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University in Prague , Hradec Kralove , Czech Republic.
245    10
$a Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter / $c M. Vytrisalova, T. Touskova, K. Ladova, L. Fuksa, V. Palicka, P. Matoulkova, P. Horak, J. Stepan,
520    9_
$a OBJECTIVES: Low adherence to treatment with bisphosphonates significantly impedes its effectiveness. The objectives were: (1) to compare adherence to oral weekly and monthly bisphosphonates with emphasis on dosing instructions; and (2) to study associations between adherence and beliefs about the bisphosphonate treatment among women ≥ 55 years. METHODS: A multicenter survey was performed in secondary-care patients with osteoporosis. Osteoporosis Specific Morisky Medication Adherence Scale (OS-MMAS), questions on compliance with five dosing instructions and Beliefs about Medicines Questionnaire (BMQ) Specific were used. RESULTS: As many as 363 questionnaires (response rate 95%) were analyzed. Respondents (mean age 69 years) were treated with weekly bisphosphonates (37%) or monthly ibandronate (63%). Based on OS-MMAS, 67% of respondents showed high adherence with no differences between the subgroups. Only 44% of respondents were compliant with all dosing instructions. Compliance with dosing instructions concerning time interval (fasting and staying upright) was 71% in weekly and 52% in monthly subgroups, respectively (p < 0.001). Compliance with dosing instructions correlated positively with education (p = 0.009). The mean BMQ necessity score of 18.4 was greater than the mean BMQ concerns score of 13.3. OS-MMAS score correlated with necessity (p = 0.010). Persistence derived from OS-MMAS correlated with both necessity (p = 0.014) and concerns (p = 0.041). CONCLUSION: Despite relatively high adherence to the treatment, most patients do not follow dosing instructions. Reduced bioavailability, particularly of monthly ibandronate, can be expected in clinical practice. Adherence-related outcomes are associated with beliefs about the oral treatment with bisphosphonates.
650    _2
$a aplikace orální $7 D000284
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory kostní resorpce $x aplikace a dávkování $x terapeutické užití $7 D050071
650    _2
$a průřezové studie $7 D003430
650    _2
$a bisfosfonáty $x aplikace a dávkování $x terapeutické užití $7 D004164
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průzkumy zdravotní péče $7 D019538
650    12
$a zdraví - znalosti, postoje, praxe $7 D007722
650    _2
$a lidé $7 D006801
650    _2
$a adherence k farmakoterapii $x psychologie $x statistika a číselné údaje $7 D055118
650    _2
$a lidé středního věku $7 D008875
650    _2
$a postmenopauzální osteoporóza $x farmakoterapie $x psychologie $7 D015663
650    _2
$a průzkumy a dotazníky $7 D011795
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Touskova, T
700    1_
$a Malá-Ládová, Kateřina $7 xx0220369
700    1_
$a Fuksa, L
700    1_
$a Palicka, V
700    1_
$a Matoulkova, P
700    1_
$a Horak, P
700    1_
$a Stepan, J
773    0_
$w MED00005023 $t Climacteric the journal of the International Menopause Society $x 1473-0804 $g Roč. 18, č. 4 (2015), s. 608-16
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25495333 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20180117094640 $b ABA008
999    __
$a ok $b bmc $g 1114096 $s 935035
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 18 $c 4 $d 608-16 $e 20150224 $i 1473-0804 $m Climacteric $n Climacteric $x MED00005023
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...